“The Thyroid Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thyroid Cancer pipeline products will significantly revolutionize the Thyroid Cancer market dynamics”
The Thyroid Cancer market report provides current treatment practices, emerging drugs, Thyroid Cancer market share of individual therapies, and current and forecasted Thyroid Cancer market size from 2019 to 2032, segmented by seven major markets. The report also covers current Thyroid Cancer treatment practices/algorithms and Thyroid Cancer unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Key takeaways from the Thyroid Cancer Market Research Report
- The Thyroid Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- As per Surveillance, Epidemiology, and End Results (SEER), Thyroid cancer accounts for 43,800 new cases in the United States; in 2022
- The rate of new cases of thyroid cancer was 15.7 per 100,000 men and women per year. The death rate was 0.5 per 100,000 men and women per year
- The leading Thyroid Cancer Market Companies include Novartis, AffyImmune Therapeutics, Eli Lilly, LoxoOncology, AstraZeneca, Eisai Inc, Merck Sharp & Dohme LLC, Bayer, Genzyme, Exelixis and others
- Promising Thyroid Cancer Therapies include Dabrafenib, Trametinib, AIC 100, LOXO-260, Durvalumaband, tremelimumab, and others.
Discover more about therapies set to grab major Thyroid Cancer Market Share @ Thyroid Cancer Market Size
Thyroid Cancer Overview
Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States.
Thyroid Cancer Epidemiology Segmentation in the 7MM
- Total Thyroid Cancer Prevalence
- Thyroid Cancer Prevalent Cases of by severity
- Thyroid Cancer Gender-specific Prevalence
- Thyroid Cancer Diagnosed Cases of Episodic and Chronic
Download the report to understand which factors are driving Thyroid Cancer epidemiology trends @ Thyroid Cancer Epidemiological Insights
Recent Developmental Activities in the Thyroid Cancer Treatment Landscape
- Donafenib, an orally administered multikinase inhibitor, is being developed by Suzhou Zelgen Biopharmaceuticals for the treatment of Late stage cancers. The product targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
- Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.
- RX108 is a novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase). Na+/K+-ATPase is an ion carrier protein and controls transportation of Na+ and K+ across the cell membrane. Studies have shown that Na+/K+-ATPase serves as a scaffold for the assembly of multiple-protein signaling complex and plays an important role in the regulation of cell growth, motility, and proliferation beyond that of ion transport. Expression of Na+/K+-ATPase is elevated in various tumors. Inhibition of Na+/K+-ATPase in cancer cells triggers a series of downstream signaling activities that lead to cell-cycle arrest, apoptosis and autophagic cell death. Targeting Na+/K+-ATPase offers a potential new approach for the development of novel anti-cancer therapies.
Thyroid Cancer Emerging Drugs Profile
- Donafenib: Suzhou Zelgen Biopharmaceuticals
Donafenib, an orally administered multikinase inhibitor, is being developed by Suzhou Zelgen Biopharmaceuticals for the treatment of Late stage cancers. The product targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
- Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
Anlotinib is an orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
- Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.
To know more about Thyroid Cancer Emerging Drugs & Companies, visit @ Thyroid Cancer Treatment Landscape
Thyroid Cancer Companies and Pipeline Therapies
- Loxo Oncology Inc: Selpercatinib
- Eli Lilly and Company: Cabozantinib
- Eisai Inc : Lenvatinib
- Merck Sharp & Dohme LLC: Lenvatinib Matching
- Bayer: Sorafenib (Nexavar, BAY43-9006)
- Genzyme, a Sanofi Company: Vandetanib (SAR390530)
- Exelixis: XL184
- Novartis Pharmaceuticals: Dabrafenib
- Suzhou Zelgen Biopharmaceuticals Co. Ltd: Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)
Thyroid Cancer Treatment Market
The treatment pattern includes radiation therapy, hormonal therapy, chemotherapy, targeted drug therapy, and surgery. Treatment after surgery depends on the stage of cancer, Radioactive iodine (RAI) treatment is sometimes used after thyroidectomy for early-stage cancers (T1 or T2), but RAI therapy is often given for more advanced cancers such as T3 or T4 tumors, or cancers that have spread to lymph nodes or distant areas. The goal is to destroy any remaining thyroid tissue and to try to treat any cancer remaining in the body.
Learn more about the Thyroid Cancer Pipeline Therapies in clinical trials @ New Treatment for Thyroid Cancer
Scope of the Thyroid Cancer Market Report
- Coverage- 7MM
- Thyroid Cancer Market Companies- Novartis (NYSE: NVS), AffyImmune Therapeutics, Eli Lilly (NYSE: LLY), LoxoOncology (NYSE: LOXO), AstraZeneca (NYSE: AZN), and others
- Thyroid Cancer Pipeline Therapies- Dabrafenib, Trametinib, AIC 100, LOXO-260, Durvalumaband, tremelimumab, and others.
- Thyroid Cancer Market Dynamics: Thyroid Cancer Market Drivers and Barriers
Discover more about Thyroid Cancer Drugs in development @ Thyroid Cancer Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Executive Summary of Thyroid Cancer
- Competitive Intelligence Analysis for Thyroid Cancer
- Thyroid Cancer: Market Overview at a Glance
- Thyroid Cancer: Disease Background and Overview
- Patient Journey
- Thyroid Cancer Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Thyroid Cancer Unmet Needs
- Key Endpoints of Thyroid Cancer Treatment
- Thyroid Cancer Marketed Products
- Thyroid Cancer Emerging Therapies
- Thyroid Cancer: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Thyroid Cancer
- KOL Views
- Thyroid Cancer Market Drivers
- Thyroid Cancer Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Get in touch with our Business executive @ Thyroid Cancer Market Drivers and Barriers
List of Top Selling Market Research Reports in 2023
Transient Ischemic Attack Market | Surgical Sealant Market | Supraventricular Tachycardia Market | Stem Cell Market | Scoliosis Market | Ranibizumab Biosimilars Insight | Pigment Epithelial Detachment Market | Percutaneous Arterial Closure Device Market | Pediatric Growth Hormone Deficiency PGHD Market | Inflammatory Pain Market
Latest Blogs Provided By DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com